Đaković Rode Oktavija, Bodulić Kristian, Zember Sanja, Cetinić Balent Nataša, Novokmet Anđa, Čulo Marija, Rašić Željka, Mikulić Radojka, Markotić Alemka
Department for Clinical Microbiology, Division for Virology, University Hospital for Infectious Diseases "Dr. Fran Mihaljević", 10000 Zagreb, Croatia.
School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Vaccines (Basel). 2022 Jan 20;10(2):153. doi: 10.3390/vaccines10020153.
Research on post-vaccination antibody dynamics has become pivotal in estimating COVID-19 vaccine efficacy. We studied anti-SARS-CoV-2 Spike RBD IgG levels in 587 healthcare workers (2038 sera) who completed BNT162b2 vaccination. Average antibody titer 3 weeks after the first dose in COVID-19-naïve participants (median 873.5 AU/mL) was 18-fold higher than the test threshold, with a significant increase 1 month (median 9927.2 AU/mL) and an exponential decrease 3 (median 2976.7 AU/mL) and 6 (median 966.0 AU/mL) months after complete vaccination. Participants with a history of COVID-19 prior to vaccination showed significantly higher antibody levels, particularly after the first dose (median 14,280.2 AU/mL), with a slight decline 1 month (median 12,700.0 AU/mL) and an exponential decline in antibody titers 3 (median 4831.0 AU/mL) and 6 (median 1465.2 AU/mL) months after vaccination. Antibody levels of COVID-19-naïve subjects after the first dose were moderately correlated with age ( = -0.4). Multivariate analysis showed a strong independent correlation between IgG levels 6 months after vaccination and both IgG titers after the first dose and 1 month after vaccination ( = 0.709). Regardless of pre-vaccination COVID-19 history, IgG levels 6 months after vaccination were comparable to antibody levels reached by COVID-19-naïve participants after the first vaccine dose.
疫苗接种后抗体动态的研究对于评估新冠疫苗的效力至关重要。我们研究了587名完成BNT162b2疫苗接种的医护人员（2038份血清）中抗SARS-CoV-2刺突受体结合域（Spike RBD）IgG水平。未感染过新冠病毒的参与者在首剂接种3周后的平均抗体滴度（中位数为873.5 AU/mL）比检测阈值高18倍，在完全接种疫苗后1个月（中位数为9927.2 AU/mL）显著升高，在接种后3个月（中位数为2976.7 AU/mL）和6个月（中位数为966.0 AU/mL）呈指数下降。接种疫苗前有新冠病毒感染史的参与者抗体水平显著更高，尤其是在首剂接种后（中位数为14280.2 AU/mL），在接种后1个月略有下降（中位数为12700.0 AU/mL），在接种后3个月（中位数为4831.0 AU/mL）和6个月（中位数为1465.2 AU/mL）抗体滴度呈指数下降。未感染过新冠病毒的受试者在首剂接种后的抗体水平与年龄呈中度相关（r = -0.4）。多变量分析显示，接种疫苗后6个月的IgG水平与首剂接种后和接种后1个月的IgG滴度均呈强独立相关（r = 0.709）。无论接种疫苗前的新冠病毒感染史如何，接种疫苗后6个月的IgG水平与未感染过新冠病毒的参与者在首剂疫苗接种后达到的抗体水平相当。
